Revelation Biosciences, Inc.
REVBW
NASDAQ Global Market0.01
USD
+0.00
- -
CIK
0001810560
ISIN
US76135L1199
CUSIP
76135L119
Return %
Stock
S&P500
1Y
-50.00
19.01
3Y
-66.33
65.48
5Y
-99.03
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- James Rolke
- Full Time Employees
- 8
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4660 La Jolla Village Drive San Diego CA United States of America 10010
- IPO Date
- Jan 11, 2022
- CIK
- 0001810560
- Website
- revbiosciences.com
- Similar Companies
- Business
- Revelation Biosciences, Inc. operates as a biotechnology company specializing in the development and commercialization of innovative blood test platforms and diagnostics designed to monitor and manage chronic diseases, primarily focusing on cardiovascular and neurological conditions. The company's core products include proprietary biomarker platforms that support point-of-care diagnostic tests and precision medicine applications, aimed at improving patient outcomes through early detection and disease management. It provides solutions such as blood-based biomarker tests for cardiovascular risk assessment, neurodegenerative disease monitoring, and inflammation analysis. Revelation Biosciences serves healthcare providers and researchers, with operational reach primarily in the United States, and collaborates within the healthcare and medical research industries. Founded in 2011, Revelation Biosciences is headquartered in South San Francisco, California. The company has recently advanced its strategic growth through partnerships and product development initiatives, including the launch of next-generation assays to expand the precision and scope of its diagnostic offerings. In the last 1-2 years, Revelation Biosciences has focused on enhancing its technology platforms and expanding clinical trial collaborations to validate and commercialize its biomarker-based tests. This includes recent strategic alliances aimed at driving innovation in chronic disease diagnostics and potentially broadening its market presence through new healthcare provider partnerships. These developments demonstrate the company's commitment to evolving its product portfolio and advancing personalized medicine solutions. Revelation Biosciences also maintains strategic relationships in the biotech and medical device sectors to support its research, product development, and commercialization efforts. The company operates primarily in the biotechnology and diagnostics industry segments, targeting healthcare institutions, clinical researchers, and pharmaceutical companies involved in chronic disease management and precision medicine. As part of its business model, Revelation Biosciences emphasizes research-driven innovation and clinical validation to enhance diagnostic accuracy and patient care. Its ongoing investments in technology and collaborative research underpin its position as a growing player in the clinical diagnostics market. No major corporate reorganizations, name changes, or acquisitions have been publicly reported very recently, but the company continues to pursue innovation and partnerships to strengthen its product offerings and operational footprint within the medical diagnostics sector. Detailed and up-to-date information about specific recent funding rounds or acquisitions was not clearly available, suggesting a steady focus on organic growth and strategic collaborations. Revelation Biosciences remains a vital entity headquartered in California with a clear focus on biomarker-based diagnostic platforms for chronic disease management. This profile provides an encompassing view of Revelation Biosciences, Inc., emphasizing its product lines, industry positioning, recent strategic developments, and corporate fundamentals in line with the standards of financial data providers.